Cargando…

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement

INTRODUCTION: While adalimumab is licensed for ankylosing spondylitis (AS), open uncontrolled studies suggest therapeutic efficacy of TNF-inhibitors in juvenile onset AS (JoAS). METHODS: A total of 32 patients aged 12 to 17 years with severe, active and refractory JoAS were enrolled in a multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horneff, Gerd, Fitter, Sigrid, Foeldvari, Ivan, Minden, Kirsten, Kuemmerle-Deschner, Jasmin, Tzaribacev, Nicolay, Thon, Angelika, Borte, Michael, Ganser, Gerd, Trauzeddel, Rolf, Huppertz, Hans-Iko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580542/ https://www.ncbi.nlm.nih.gov/pubmed/23095307 http://dx.doi.org/10.1186/ar4072

Ejemplares similares

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab
por: Horneff, G, et al.
Publicado: (2011)

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
por: Armaroli, Giulia, et al.
Publicado: (2020)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long‐Term Safety Data from the German BIKER Registry
por: Klein, Ariane, et al.
Publicado: (2019)

Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past
por: Huppertz, Hans-Iko, et al.
Publicado: (2011)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach, Aziza, et al.
Publicado: (2014)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Holzinger, Dirk, et al.
Publicado: (2018)

Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis
por: Chen, Zena, et al.
Publicado: (2021)

Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis
por: Persaud, Trevor, et al.
Publicado: (2022)

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
por: Ding, Xiaoliang, et al.
Publicado: (2020)

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
por: Hennigan, Stephanie, et al.
Publicado: (2007)

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Bosnić, Dubravka, et al.
Publicado: (2016)

Allergic bronchopulmonary aspergillosis in a patient with ankylosing spondylitis treated with adalimumab
por: Suzuki, Yudai, et al.
Publicado: (2021)

Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
por: Lee, Sang‐Hoon, et al.
Publicado: (2020)

Eosinophilia in a patient with ankylosing spondylitis treated with prolonged adalimumab only
por: He, Junhong, et al.
Publicado: (2022)

Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
por: Liu, Ying, et al.
Publicado: (2022)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Comparison of the Japanese Orthopaedic Association (JOA) Score and Modified JOA (mJOA) Score for the Assessment of Cervical Myelopathy: A Multicenter Observational Study
por: Kato, So, et al.
Publicado: (2015)

Correction: Comparison of the Japanese Orthopaedic Association (JOA) Score and Modified JOA (mJOA) Score for the Assessment of Cervical Myelopathy: A Multicenter Observational Study
Publicado: (2015)

Comparison Between the Japanese Orthopaedic Association (JOA) Score and Patient-Reported JOA (PRO-JOA) Score to Evaluate Surgical Outcomes of Degenerative Cervical Myelopathy
por: Oshima, Yasushi, et al.
Publicado: (2020)

A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment
por: Yoon, Ji Ha, et al.
Publicado: (2022)

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
por: Rudwaleit, Martin, et al.
Publicado: (2010)

The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
por: Chopra, Arvind, et al.
Publicado: (2023)

The role of the JOA in the globalization of orthopedics
por: Iwamoto, Yukihide
Publicado: (2009)

Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2017)

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
por: Maksymowych, Walter P., et al.
Publicado: (2018)

Lobular capillary hemangioma in a patient with ankylosing spondylitis using adalimumab: an exuberant presentation()()
por: Silva, Thadeu Santos, et al.
Publicado: (2019)

Optical coherence tomography changes in ankylosing spondylitis patients on long-term adalimumab treatment
por: Yavuz, Nurce Cilesizoglu, et al.
Publicado: (2022)

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany
por: Heiligenhaus, Arnd, et al.
Publicado: (2020)

Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany
por: Sengler, Claudia, et al.
Publicado: (2021)

80th anniversary of the founding of the JOA
por: Yamamuro, Takao
Publicado: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
por: van der Heijde, D, et al.
Publicado: (2008)

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
por: van der Heijde, Désirée, et al.
Publicado: (2009)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_kg1l0fkja1o9ls1017c0cvmh4d